Requip PD 24 Hour

Requip PD 24 Hour Adverse Reactions





Zuellig Pharma
Full Prescribing Info
Adverse Reactions
Adverse reactions are tabulated as follows according to the indication. The overall safety profile of ropinirole comprises adverse reactions from all indications from clinical trial data and from post-marketing experience.
Adverse events are listed in Table 4 by system organ class and frequency. Frequencies are defined as : very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1,000), very rare (<1/10,000), including isolated reports.
Clinical Trial Data: The tables as follow list the adverse drug reactions reported at a higher rate with ropinirole than placebo or a higher or comparable rate to comparator in clinical trials.
Adverse drug reactions reported from patients with parkinson's disease: Unless otherwise indicated, the data in the following table was observed with both immediate release and prolonged release formulations. (See Table 4.)

Click on icon to see table/diagram/image

Adverse drug reactions reported during clinical trials in patients with restless legs syndrome: (See Table 5.)

Click on icon to see table/diagram/image

Post Marketing Data: (See Table 6.)

Click on icon to see table/diagram/image
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in